INTRODUCTION
============

Darier's disease (DD, keratosis follicularis: OMIM\#124200) is a genetic keratinization disorder with autosomal dominant inheritance. DD shows almost complete penetrance. Patients with DD have been reported around the world, and the prevalence of DD is estimated to be between 1/36,000 and 1/100,000.^[@ref1])^ Disease phenotypes of DD are not seen in infancy in most cases, and the disease frequently occurs in childhood and adolescence.^[@ref2])^ Patients with DD show various skin manifestations, including keratotic papules on the chest and the forehead, verrucous papules on the hands and the feet, hemorrhagic vesicles on the acral areas of the extremities and vegetative lesions in the intertriginous regions. DD sometimes shows neuropsychiatric manifestations.^[@ref3])^

Most cases of DD are caused by mutations in *ATP2A2*. *ATP2A2* is expressed in both the skin and the brain and encodes type 2 sarcoendoplasmic reticulum calcium-ATPase (SERCA2). SERCA2 works in establishing ion gradients by pumping ions across biological membranes. Two calcium ions can be transported for each ATP that is hydrolysed, and 2 or 3 hydrogen ions are counter-transported. Active removal of calcium ions from the cytosol is a critical step of signal transduction pathways in animal cells, facilitating the rapid cytosolic calcium ion oscillations that are required for a wide range of physiological functions, such as muscle contraction, neuronal transmission, cellular motility and cell growth. SERCA2b is ubiquitously expressed, but expression is particularly high in keratinocytes. SERCA2b has 11 transmembrane helix domains (TMs), TM1-TM11, and there are 9 calcium binding residues (CBRs) in TM4, 5, 6 and 8. SERCA2b has 3 cytoplasmic globular domains: an actuator or anchor domain (the A domain), a phosphorylation domain (the P domain) and a nucleotide binding domain (the N domain).^[@ref4])^ When calcium ions are released and a pathway for entry of new calcium ions is created, three extramembranous domains gather to form a single headpiece, and TMs exhibit large-scale rearrangement.^[@ref5])^ Causative abnormalities in the adhesion of epidermal keratinocytes have been proposed from the fact that acantholytic cells show aberrant distribution of desmosomal components.^[@ref6])^ A review of the literature on *ATP2A2* mutations and DD phenotypes suggested certain genotype/phenotype correlations.^[@ref3])^

Here, we report 5 mutations in 5 DD patients from 5 independent families, including 1 previously unreported mutation in *ATP2A2.*

MATERIALS AND METHODS
=====================

Patients
--------

We analyzed 5 Japanese patients from 5 independent families who presented or were referred to our department in the past 5 years ([Table 1](#table1){ref-type="table"}). The clinical features and *ATP2A2* mutations in Case 3 and Case 4 were reported previously,^[@ref7],\ [@ref8])^ and the clinical features of Case 5 were reported previously.^[@ref9])^ Detailed clinical features of each patient are as follows.

###### 

Summary of clinical features and genotypes in the present series of DD patients

  Case   Age (year)   Sex      Nucleotide change                        Amino acid change          Mutation site (functional domain)                      Age of onset (years)   Severity of skin symptoms   Affected family members
  ------ ------------ -------- ---------------------------------------- -------------------------- ------------------------------------------------------ ---------------------- --------------------------- -------------------------
  1      40           female   c.2255_2257del (previously unreported)   p.Ile752_Tyr753delinsAsn   stalk domain                                           7                      moderate                    father, sister
  2      43           male     c.548A\>T                                p.Glu183Val                A domain                                               33                     moderate                    father
  3      40           female   c.2721A\>C                               p.Glu907Asp                transmembrane helix domain (calcium-binding residue)   40                     mild                        none
  4      66           male     c.953G\>A                                p.Cys318Tyr                stalk domain                                           64                     moderate                    none
  5      84           male     c.391C\>T                                p.Arg131\*                 A domain (truncation)                                  74                     mild                        none

Case 1
------

A 40-year-old woman presented with multiple brown papules with itching on her entire body surface, especially on the seborrheic areas ([Fig. 1](#fig1){ref-type="fig"}). She had been suffering from DD for 5 years. Her father and sister had similar symptoms.

![Clinical features of Case 1. Multiple brown papules with crusts are present on the abdomen (A), and the hands (B).](2186-3326-78-0485-g001){#fig1}

Case 2
------

A 43-year-old man presented with brown papules on his neck, breast and forearms, which had existed for ten years when he began topical adapalene treatment. The papules exacerbated during summer, and they were itchy. His father had similar symptoms. A skin biopsy specimen from the lesion showed acantholysis and abnormal keratinization ([Fig. 2](#fig2){ref-type="fig"}). Keratotic tiers and suprabasal cleft formation were also seen.

![Histopathological features of the skin lesions of DD. A skin biopsy specimen from Case 2 shows typical histopathological features of DD, marked hyperkeratosis, acantholysis, and clefts and dyskeratosis in the suprabasal layers of epidermis. Haematoxylin-eosin stain, original magnification X400.](2186-3326-78-0485-g002){#fig2}

Case 3
------

A 40-year-old woman presented with intensely pruritic reddish follicular papules. She had neither family history nor other serious complications. The papules had first appeared less than 1 year previously on the back and the breast, and had exacerbated in the first month after onset. Slight hyperkeratosis was seen on the wrist, and erythema appeared on the hand. One follicular papule was excised and submitted for histopathological examination. High-power microscopy showed suprabasal acantholysis and well-developed corps ronds and grains. We reported this patient elsewhere in 2015.^[@ref7])^

Case 4
------

A 66-year-old Japanese man presented with multiple brown papules with crusts on the seborrheic areas of the head and face, and on the neck, abdomen, back and legs. Partially exudative hyperkeratotic lesions with odor were seen on the forehead, the nasal wings and the intertriginous areas. He had been diagnosed with schizophrenia and intellectual disability at the age of 63. Light microscopy of a lesional skin biopsy from his neck revealed hyperkeratosis, acantholysis, clefts, grains and corps ronds in the epidermis. This case was reported in 2016 as "DD complicated with schizophrenia".^[@ref8])^

Case 5
------

An 84-year-old man had been suffering from DD for 10 years. The age of onset was notably late. He presented with multiple brown papules with crusts, especially on his trunk. His nails showed whitish striae and wedged recesses (so-called "notches"). The clinical features of this case were previously reported in Japanese.^[@ref9])^

Evaluation of disease severity of DD
------------------------------------

The severity of DD for each patient was classified according to the methods described in the previous report.^[@ref1])^ Briefly, patients with only grouped keratotic papules in the disease predilection areas were classified as having the mild phenotype. Cases showing widespread papules or localized verrucous plaques were judged to have moderate disease severity. Extensive, hyperkeratotic and macerated plaques and/or hypertrophic growth in the intertriginous areas were thought to be signs of the severe phenotype.

Sanger sequencing and whole exome sequencing
--------------------------------------------

Ethical approval was obtained and all research was performed in accordance with the *Declaration of Helsinki* principles. Genomic DNA from the patient's peripheral blood leukocytes was used for Sanger sequencing analysis and whole exome sequencing analysis, as described previously.^[@ref10],\ [@ref11])^ Briefly, for whole exome sequencing, genomic DNA from the proband was enriched for protein-coding sequences with the SureSelect Human All Exon V5 kit (Agilent Technologies, Santa Clara, CA, USA). Massively parallel sequencing was performed with the HiSeq 2500 platform with 100 bp paired-end reads (Illumina, San Diego, CA, USA). Candidate germline variants were identified through our in-house pipeline for exome-sequencing analysis with minor modifications. The obtained sequences were aligned with the UCSC Genome Browser hg19 by using the Burrows-Wheeler Aligner.

RESULTS
=======

Mutation detection
------------------

*ATP2A2* mutations detected in the present DD cases and their consequences are summarized in [Table 1](#table1){ref-type="table"}.

Case 1
------

Whole exome sequencing analysis revealed the previously unreported deletion mutation c.2255_2257del. DNA samples from the peripheral blood of the patient and her parents and sister were analyzed by Sanger sequencing to confirm the mutation. This revealed that the patient was heterozygous for the deletion mutation ([Fig. 3](#fig3){ref-type="fig"}). This deletion results in the deletion/insertion p.Ile752_Tyr753delinsAsn. Her father and sister were also heterogeneous for the identical mutation in *ATP2A2*, although her mother had only wild-type alleles.

![Sanger sequencing of *ATP2A2* in Case 1. Direct sequencing reveals a heterozygous mutation within *ATP2A2,* c.2255_2257del (p.Ile752_Tyr753delinsAsn) in the patient.](2186-3326-78-0485-g003){#fig3}

Case 2
------

Sanger sequencing of the entire coding regions of *ATP2A2* revealed the missense mutation c.548A\>T (p.Glu183Val), which was previously reported in a Japanese patient with DD.^[@ref12])^ Glu183 is in the A domain, which works as a lever when calcium ions go through SERCA2.

Case 3
------

Sanger sequencing of the entire coding regions of *ATP2A2* revealed the missense mutation c.2721A\>C (p.Glu907Asp). The mutation analysis in this patient was previously reported elsewhere.^[@ref7])^ This mutation resulted in an alteration of a calcium-binding residue.

Case 4
------

By Sanger sequencing, the missense mutation c.953G\>A (p.Cys318Tyr) was found in the patient's *ATP2A2*.^[@ref8])^ The mutation changes an amino acid in the stalk 4 domain of the molecule. The stalk domain connects the P domain and TM4.

Case 5
------

Sanger sequencing of the entire coding regions of *ATP2A2* revealed the nonsense mutation c391C\>T (p.Arg131\*).^[@ref13])^ This nonsense mutation is located in the A domain, one of the three major domains on the cytoplasmic surface of SERCA2. The mutation site is close to the N-terminus of SERCA2, and p.Arg131\* results in a serious truncation of the SERCA2 peptide, causing SERCA2 to lose most of its structure, including the cytoplasmic P domain and the N domain. In addition, there is a possibility that nonsense-mediated mRNA decay might lead to a loss of mutant SERCA2 products in the present patient.

In silico relevance analysis of the novel mutation in Case 1
------------------------------------------------------------

The novel deletion/insertion mutation p.Ile752_Tyr753delinsAsn was not found in the Human Genetic Variation Database, including in 1,208 exome datasets from normal controls (http//www.genome.med.kyoto-u.ac.jp/SnpDB/index.html). The mutation was analyzed using PROVEAN (http://provean.jcvi.org/). The PROVEAN program predicts that the present mutation p.Ile752_Tyr753delinsAsn has "deleterious" effects on the SERCA2 structure/function.

Evaluation of skin phenotype severity in the DD patients
--------------------------------------------------------

The severity of skin symptoms in the present DD patients is summarized in [Table 1](#table1){ref-type="table"}. Three of the five patients had moderate skin symptoms, and the other two showed the mild skin phenotype.

DISCUSSION
==========

Light microscopy of a skin biopsy reveals hyperkeratosis, acantholysis, cleft, grains and corps ronds in the epidermis in DD patients. Such morphological features indicate cell-cell adhesion abnormality and keratinocyte differentiation abnormality in DD. In fact, acantholytic cells show aberrant distribution of desmosomal components.^[@ref6])^ Thus, pathogenic defects of keratinocyte structure and adhesion have been proposed as the cause of DD.

SERCA2b has 11 TMs. There are 10 CBRs in TMs in the transmembrane region.^[@ref4])^ SERCA2b has three major cytoplasmic globular domains, A domain, P domain and N domain. The three cytoplasmic globular domains play an important role when calcium ions bind and change their positions.

Genotype/phenotype correlations between *ATP2A2* mutations and DD phenotypes are still unknown. We found five distinct, heterozygous mutations in five patients from five independent families. The mutations consisted of three missense, one nonsense and one deletion mutations ([Table 1](#table1){ref-type="table"}. Four mutations out of five were previously reported^[@ref7],\ [@ref8],\ [@ref12],\ [@ref13])^ and the other one has not been reported previously. The mutations and their consequences are summarized in [Table 1](#table1){ref-type="table"}.

In Case 1, we detected a previously unreported three-base deletion mutation c.2255_2257del (p.Ile752_Tyr753delinsAsn) in *ATP2A2*. The amino acids altered by the mutation localize in a stalk domain behind N domain and the hinge domain. Other three-base deletion mutations in *ATP2A2* were reported previously in the literature.^[@ref1],\ [@ref14])^ In the present study, the PROVEAN program predicts that the deletion mutation is "deleterious". The PROVEAN (protein variation effect analyzer) is a software which forecasts whether a missense or an indel mutation affects the function of a protein.^[@ref15])^ The PROVEAN is a powerful tool to screen out functionally significant nonsynonymous or indel variants.^[@ref15])^ In Case 1, the novel mutation c.2255_2257del (p.Ile752_Tyr753delinsAsn) in exon 15 affects both isoforms, SERCA2a and SERCA2b. SERCA2a is known to be expressed favorably in skeletal and cardiac muscles. However, the patient had no apparent symptom other than the skin manifestations.

Case 3 had the missense mutation of one calcium binding residue which is important for the function of SERCA2. Case 5 had the serious truncation mutation, losing most part of the SERCA2 peptide. Thus, both in Case 3 and Case 5, the mutations are thought to have serious effects on the SERCA2 function. However, DD skin symptoms of both patients were mild. Especially, Case 5 had had no apparent DD phenotype until over 70 years of age, indicating that DD skin manifestations were mild in this patient.

In Case 4, we detected the missense mutation p.Cys318Tyr in a stalk domain which is thought to be not so important for the SERCA2 function. However, the skin symptoms were moderate in Case 4 and, in addition, the patient had schizophrenia, which might be a complication of DD. In a recent Swedish cohort study, 6 of 770 DD patients (0.8%) were found to have schizophrenia.^[@ref16])^ It was determined that individuals with DD had a 2.3 times higher risk of being diagnosed with schizophrenia than matched individuals from the general population.

Ahn *et al.* reported that several mutants which cause severe phenotypes of DD inhibited the activity of the endogeneous and the co-expressed wild type SERCA2b *in vivo*.^[@ref17])^ If this is the case, it is difficult to speculate the total SERCA2 activity in the patients' keratinocytes, simply from the nature and sites of the *ATP2A2* mutations. In the present DD cases, there was no significant genotype/phenotype correlation between the *ATP2A2* mutation sites and nature and the severity of DD phenotypes.

ACKNOWLEDGMENTS
===============

The authors thank Ms. Haruka Ozeki and Ms. Yuka Terashita for their technical help in analyzing mutations of *ATP2A2*. This study was supported by JSPS KAKENHI Grant Numbers 15H04887, 15K15415, 15H04886, 15K15414 and 15H06280. The work was also supported by the Japan Intractable Diseases Research Foundation.

CONFLICT OF INTEREST
====================

The authors declare that there is no duality of interest.

[^1]: Corresponding author: Masashi Akiyama, MD, PhD

    Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

    Tel: +81-52-744-2314, Fax: +81-52-744-2318, E-mail: makiyama\@med.nagoya-u.ac.jp
